FDA inspects Hovione's API manufacturing plant in Macau
Hovione's active pharmaceutical ingredients plant in Macau underwent a pre-approval inspection by FDA
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Hovione's active pharmaceutical ingredients plant in Macau underwent a pre-approval inspection by FDA
Hovione is expanding its scientific know-how and industrial production capabilities on a variety of technologies to widen its ability to provide customized solutions for advanced APIs (aAPI™).
Hovione announces that the consolidated sales volume for the fiscal year ended 31st March 2004 amounted to US$75m, representing a growth of 9% over the previous year.
Hovione and CyDex, today announced an alliance to develop and commercialize improved formulations of drugs that are off-patent or soon will be off-patent.
By Jorge Pastilha, Director of Logistics & Control and Filipe Gaspar, PhD, Process Engineer
To Mrs. Margot Wallström - Commissioner for the Environment, EU Commission, Brussels
Hovione is pleased to announce that it has installed a new state-of-the-art Spray Drying facility to address the latest technology in particle design.